Effects of parathyroid hormone 1-34 on osteogenic and chondrogenic differentiation of human fracture haematoma-derived cells<i>in vitro</i>

Dogaki, Yoshihiro; Lee, Sang Yang; Niikura, Takahiro; Koga, Takaaki; Okumachi, Etsuko; Nishida, Kotaro; Kuroda, Ryosuke; Kurosaka, Masahiro

doi:10.1002/term.1818

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have identified potential mechanisms by which PTH (1–34) may enhance fracture healing [ 6 , 15 , 38 ]. PTH (1–34) may enhance fracture healing by two mechanisms: firstly by stimulating the differentiation of osteoblasts and secondly by promoting chondrocyte proliferation and differentiation and accelerating endochondral bone formation [ 9 , 11 , 39 ].…”

Section: Discussionmentioning

confidence: 99%

Triweekly administration of parathyroid hormone (1–34) accelerates bone healing in a rat refractory fracture model

Kumabe

Lee

Waki

et al. 2017

BMC Musculoskelet Disord

Self Cite

View full text Add to dashboard Cite

BackgroundSome reports have shown that intermittent parathyroid hormone (PTH) (1–34) treatment for patients with delayed union or nonunion have led to successful healing. In this study, we investigated whether systemic intermittent administration of PTH (1–34) has a beneficial effect on bone healing in a rat refractory fracture model.MethodsWe created a refractory femoral fracture model in 32 rats with periosteal cauterization that leads to atrophic nonunion at 8 weeks after surgery. Half the rats received subcutaneous intermittent human PTH (1–34) injections at a dosage of 100 μg/kg, thrice a week for 8 weeks. The other half received the vehicle only. At 8 weeks after fracture, radiographic, histological and mechanical assessments were performed.ResultsRadiographic assessments showed that the union rate was significantly higher in the PTH group than in the control group (P < 0.05). The degree of fracture repair as scored using the Allen grading system in histological assessment was significantly greater in the PTH group than in the control group (P < 0.05). The ultimate stress and stiffness measurements were significantly greater in the PTH group than in the control group (p < 0.05).ConclusionsWe demonstrated that triweekly administration of PTH (1–34) increased union rate and accelerated bone healing in a rat refractory fracture model, suggesting that systemic administration of PTH (1–34) could become a novel and useful therapy for accelerating fracture healing in patients at high risk of delayed union or nonunion.Electronic supplementary materialThe online version of this article (10.1186/s12891-017-1917-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Triweekly administration of parathyroid hormone (1–34) accelerates bone healing in a rat refractory fracture model

Kumabe

Lee

Waki

et al. 2017

BMC Musculoskelet Disord

Self Cite

View full text Add to dashboard Cite

show abstract

Potential effects of teriparatide (PTH (1–34)) on osteoarthritis: a systematic review

Liu

et al. 2023

Arthritis Res Ther

View full text Add to dashboard Cite

Osteoarthritis (OA) is a common and prevalent degenerative joint disease characterized by degradation of the articular cartilage. However, none of disease-modifying OA drugs is approved currently. Teriparatide (PTH (1–34)) might stimulate chondrocyte proliferation and cartilage regeneration via some uncertain mechanisms. Relevant therapies of PTH (1–34) on OA with such effects have recently gained increasing interest, but have not become widespread practice. Thus, we launch this systematic review (SR) to update the latest evidence accordingly. A comprehensive literature search was conducted in PubMed, Web of Science, MEDLINE, the Cochrane Library, and Embase from their inception to February 2022. Studies investigating the effects of the PTH (1–34) on OA were obtained. The quality assessment and descriptive summary were made of all included studies. Overall, 307 records were identified, and 33 studies were included. In vivo studies (n = 22) concluded that PTH (1–34) slowed progression of OA by alleviating cartilage degeneration and aberrant remodeling of subchondral bone (SCB). Moreover, PTH (1–34) exhibited repair of cartilage and SCB, analgesic, and anti-inflammatory effects. In vitro studies (n = 11) concluded that PTH (1–34) was important for chondrocytes via increasing the proliferation and matrix synthesis but preventing apoptosis or hypertrophy. All included studies were assessed with low or unclear risk of bias in methodological quality. The SR demonstrated that PTH (1–34) could alleviate the progression of OA. Moreover, PTH (1–34) had beneficial effects on osteoporotic OA (OPOA) models, which might be a therapeutic option for OA and OPOA treatment.

show abstract

Effects of parathyroid hormone 1-34 on osteogenic and chondrogenic differentiation of human fracture haematoma-derived cellsin vitro

Cited by 2 publications

References 32 publications

Triweekly administration of parathyroid hormone (1–34) accelerates bone healing in a rat refractory fracture model

Triweekly administration of parathyroid hormone (1–34) accelerates bone healing in a rat refractory fracture model

Potential effects of teriparatide (PTH (1–34)) on osteoarthritis: a systematic review

Contact Info

Product

Resources

About